» Articles » PMID: 32709677

Molecular Profiling of Innate Immune Response Mechanisms in Ventilator-associated Pneumonia

Abstract

Ventilator-associated pneumonia (VAP) is a common hospital-acquired infection, leading to high morbidity and mortality. Currently, bronchoalveolar lavage (BAL) is used in hospitals for VAP diagnosis and guiding treatment options. Although BAL collection procedures are invasive, alternatives such as endotracheal aspirates (ETA) may be of diagnostic value, however, their use has not been thoroughly explored. Longitudinal ETA and BAL were collected from 16 intubated patients up to 15 days, of which 11 developed VAP. We conducted a comprehensive LC-MS/MS based proteome and metabolome characterization of longitudinal ETA and BAL to detect host and pathogen responses to VAP infection. We discovered a diverse ETA proteome of the upper airways reflective of a rich and dynamic host-microbe interface. Prior to VAP diagnosis by microbial cultures from BAL, patient ETA presented characteristic signatures of reactive oxygen species and neutrophil degranulation, indicative of neutrophil mediated pathogen processing as a key host response to the VAP infection. Along with an increase in amino acids, this is suggestive of extracellular membrane degradation resulting from proteolytic activity of neutrophil proteases. The metaproteome approach successfully allowed simultaneous detection of pathogen peptides in patients' ETA, which may have potential use in diagnosis. Our findings suggest that ETA may facilitate early mechanistic insights into host-pathogen interactions associated with VAP infection and therefore provide its diagnosis and treatment.

Citing Articles

Double-layer optical fiber interferometer with bio-layer-modified reflector for label-free biosensing of inflammatory proteins.

Burnat D, Janik M, Kwietniewski N, Martychowiec A, Musolf P, Bartnik K Sci Rep. 2024; 14(1):23127.

PMID: 39367065 PMC: 11452487. DOI: 10.1038/s41598-024-70058-6.


How Does Airway Surface Liquid Composition Vary in Different Pulmonary Diseases, and How Can We Use This Knowledge to Model Microbial Infections?.

Walsh D, Bevan J, Harrison F Microorganisms. 2024; 12(4).

PMID: 38674677 PMC: 11052052. DOI: 10.3390/microorganisms12040732.


Proteomics: Unraveling the Cross Talk Between Innate Immunity and Disease Pathophysiology, Diagnostics, and Treatment Options.

Luz I, Takaya R, Ribeiro D, Castro M, Fontes W Adv Exp Med Biol. 2024; 1443:221-242.

PMID: 38409424 DOI: 10.1007/978-3-031-50624-6_12.


Integrated host/microbe metagenomics enables accurate lower respiratory tract infection diagnosis in critically ill children.

Mick E, Tsitsiklis A, Kamm J, Kalantar K, Caldera S, Lyden A J Clin Invest. 2023; 133(7).

PMID: 37009900 PMC: 10065066. DOI: 10.1172/JCI165904.


Current progress and critical challenges to overcome in the bioinformatics of mass spectrometry-based metaproteomics.

Miura N, Okuda S Comput Struct Biotechnol J. 2023; 21:1140-1150.

PMID: 36817962 PMC: 9925844. DOI: 10.1016/j.csbj.2023.01.015.


References
1.
Croce M, Swanson J, Magnotti L, Claridge J, Weinberg J, Wood G . The futility of the clinical pulmonary infection score in trauma patients. J Trauma. 2006; 60(3):523-7. DOI: 10.1097/01.ta.0000204033.78125.1b. View

2.
Palazzo S, Simpson T, Schnapp L . Biomarkers for ventilator-associated pneumonia: review of the literature. Heart Lung. 2011; 40(4):293-8. PMC: 3129391. DOI: 10.1016/j.hrtlng.2010.11.003. View

3.
Niederman M . Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. Clin Infect Dis. 2010; 51 Suppl 1:S12-7. DOI: 10.1086/653035. View

4.
Hellyer T, Anderson N, Parker J, Dark P, Van Den Broeck T, Singh S . Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial. Trials. 2016; 17(1):318. PMC: 4947254. DOI: 10.1186/s13063-016-1442-x. View

5.
Vogeli A, Ottiger M, Meier M, Steuer C, Bernasconi L, Kulkarni P . Admission levels of asymmetric and symmetric dimethylarginine predict long-term outcome in patients with community-acquired pneumonia. Respir Res. 2017; 18(1):25. PMC: 5259979. DOI: 10.1186/s12931-017-0502-4. View